{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:01Z","timestamp":1772136361991,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Foundation of Korea (NRF) grant funded by the Korean government","award":["2022R1A2C1093325"],"award-info":[{"award-number":["2022R1A2C1093325"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74191-0","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:01:48Z","timestamp":1727791308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions"],"prefix":"10.1038","volume":"14","author":[{"given":"Se-Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hyup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hyun","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Jun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"74191_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.36628\/ijhf.2021.0023","volume":"3","author":"JJ Park","year":"2021","unstructured":"Park, J. J. et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart failure. Int. J. Heart Fail.3, 224\u2013236. https:\/\/doi.org\/10.36628\/ijhf.2021.0023 (2021).","journal-title":"Int. J. Heart Fail."},{"key":"74191_CR2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ejhf.2143","volume":"23","author":"PM Seferovi\u0107","year":"2021","unstructured":"Seferovi\u0107, P. M. et al. The heart failure Association Atlas: heart failure epidemiology and management statistics 2019. Eur. J. Heart Fail.23, 906\u2013914. https:\/\/doi.org\/10.1002\/ejhf.2143 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"74191_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJMc1615918","volume":"376","author":"MM Redfield","year":"2017","unstructured":"Redfield, M. M. Heart failure with preserved ejection fraction. N. Engl. J. Med.376, 897. https:\/\/doi.org\/10.1056\/NEJMc1615918 (2017).","journal-title":"N. Engl. J. Med."},{"key":"74191_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay, S. M., Roger, V. L. & Redfield, M. M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol.14, 591\u2013602. https:\/\/doi.org\/10.1038\/nrcardio.2017.65 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"74191_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4070\/kcj.2021.0097","volume":"51","author":"HH Lee","year":"2021","unstructured":"Lee, H. H. et al. Korea Heart Disease fact sheet 2020: analysis of Nationwide Data. Korean Circ. J.51, 495\u2013503. https:\/\/doi.org\/10.4070\/kcj.2021.0097 (2021).","journal-title":"Korean Circ. J."},{"key":"74191_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","volume":"17","author":"BA Borlaug","year":"2020","unstructured":"Borlaug, B. A. Evaluation and management of heart failure with preserved ejection fraction. Nat. Rev. Cardiol.17, 559\u2013573. https:\/\/doi.org\/10.1038\/s41569-020-0363-2 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"74191_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M. et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet400, 757\u2013767. https:\/\/doi.org\/10.1016\/s0140-6736(22)01429-5 (2022).","journal-title":"Lancet"},{"key":"74191_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4070\/kcj.2021.0070","volume":"51","author":"J Oh","year":"2021","unstructured":"Oh, J., Lee, S. H., Lee, C. J. & Kang, S. M. Sodium-glucose co-transporter 2 inhibitors: a new path for heart failure treatment. Korean Circ. J.51, 399\u2013408. https:\/\/doi.org\/10.4070\/kcj.2021.0070 (2021).","journal-title":"Korean Circ. J."},{"key":"74191_CR9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in Heart failure with a preserved ejection fraction. N. Engl. J. Med.385, 1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038 (2021).","journal-title":"N. Engl. J. Med."},{"key":"74191_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med.387, 1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286 (2022).","journal-title":"N. Engl. J. Med."},{"key":"74191_CR11","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez, E. et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J.36, 2585\u20132594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338 (2015).","journal-title":"Eur. Heart J."},{"key":"74191_CR12","doi-asserted-by":"publisher","first-page":"101634","DOI":"10.1016\/j.legalmed.2019.101634","volume":"41","author":"T Shiozaki","year":"2019","unstructured":"Shiozaki, T., Sato, N., Hayashi, T., Kobayashi, K. & Asamura, H. Wild-type ATTR amyloidosis may be associated with unexpected death among the elderly. Leg. Med. (Tokyo)41, 101634. https:\/\/doi.org\/10.1016\/j.legalmed.2019.101634 (2019).","journal-title":"Leg. Med. (Tokyo)"},{"key":"74191_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen, M. et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann. Med.40, 232\u2013239. https:\/\/doi.org\/10.1080\/07853890701842988 (2008).","journal-title":"Ann. Med."},{"key":"74191_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ehf2.13693","volume":"9","author":"N Tahara","year":"2022","unstructured":"Tahara, N. et al. (99m) technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy. ESC Heart Fail.9, 251\u2013262. https:\/\/doi.org\/10.1002\/ehf2.13693 (2022).","journal-title":"ESC Heart Fail."},{"key":"74191_CR15","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/circulationaha.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore, J. D. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation133, 2404\u20132412. https:\/\/doi.org\/10.1161\/circulationaha.116.021612 (2016).","journal-title":"Circulation"},{"key":"74191_CR16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/circulationaha.121.055517","volume":"144","author":"MS Maurer","year":"2021","unstructured":"Maurer, M. S. & Ruberg, F. L. Cardiac scintigraphy and screening for transthyretin cardiac amyloidosis: caveat emptor. Circulation144, 1005\u20131007. https:\/\/doi.org\/10.1161\/circulationaha.121.055517 (2021).","journal-title":"Circulation"},{"key":"74191_CR17","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W. & Maurer, M. S. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol.73, 2872\u20132891. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"74191_CR18","doi-asserted-by":"publisher","first-page":"16584","DOI":"10.1038\/s41598-019-53119-z","volume":"9","author":"D Krishnappa","year":"2019","unstructured":"Krishnappa, D. et al. Atrial fibrillation in the elderly: the role of sub-clinical isolated cardiac amyloidosis. Sci. Rep.9, 16584. https:\/\/doi.org\/10.1038\/s41598-019-53119-z (2019).","journal-title":"Sci. Rep."},{"key":"74191_CR19","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis Treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med.379, 1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689 (2018).","journal-title":"N. Engl. J. Med."},{"key":"74191_CR20","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine, O. F. et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol.6, 1267\u20131274. https:\/\/doi.org\/10.1001\/jamacardio.2021.3070 (2021).","journal-title":"JAMA Cardiol."},{"key":"74191_CR21","doi-asserted-by":"publisher","first-page":"e0254104","DOI":"10.1371\/journal.pone.0254104","volume":"16","author":"S Goland","year":"2021","unstructured":"Goland, S. et al. Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. PLoS ONE16, e0254104. https:\/\/doi.org\/10.1371\/journal.pone.0254104 (2021).","journal-title":"PLoS ONE"},{"key":"74191_CR22","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark, P., Sletten, K., Johansson, B. & Cornwell, G. G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. U.S.A.87, 2843\u20132845. https:\/\/doi.org\/10.1073\/pnas.87.7.2843 (1990).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"74191_CR23","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1002\/ehf2.13360","volume":"8","author":"A Devesa","year":"2021","unstructured":"Devesa, A. et al. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail.8, 2856\u20132865. https:\/\/doi.org\/10.1002\/ehf2.13360 (2021).","journal-title":"ESC Heart Fail."},{"key":"74191_CR24","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1002\/ehf2.12986","volume":"7","author":"F Kocher","year":"2020","unstructured":"Kocher, F. et al. Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis. ESC Heart Fail.7, 3919\u20133928. https:\/\/doi.org\/10.1002\/ehf2.12986 (2020).","journal-title":"ESC Heart Fail."},{"key":"74191_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/circulationaha.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane, T. et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation140, 16\u201326. https:\/\/doi.org\/10.1161\/circulationaha.118.038169 (2019).","journal-title":"Circulation"},{"key":"74191_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","volume":"21","author":"PM Seferovi\u0107","year":"2019","unstructured":"Seferovi\u0107, P. M. et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail.21, 553\u2013576. https:\/\/doi.org\/10.1002\/ejhf.1461 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"74191_CR27","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/circulationaha.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou, A. et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation146, 1657\u20131670. https:\/\/doi.org\/10.1161\/circulationaha.122.060852 (2022).","journal-title":"Circulation"},{"key":"74191_CR28","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s12350-019-01950-2","volume":"28","author":"F Minutoli","year":"2021","unstructured":"Minutoli, F. et al. Serial scanning with (99m)Tc-3, 3-diphosphono-1, 2-propanodicarboxylic acid ((99m)Tc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation. J. Nucl. Cardiol.28, 1949\u20131957. https:\/\/doi.org\/10.1007\/s12350-019-01950-2 (2021).","journal-title":"J. Nucl. Cardiol."},{"key":"74191_CR29","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/openhrt-2015-000289","volume":"3","author":"T Damy","year":"2016","unstructured":"Damy, T. et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open. Heart3, e000289. https:\/\/doi.org\/10.1136\/openhrt-2015-000289 (2016).","journal-title":"Open. Heart"},{"key":"74191_CR30","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/circulationaha.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi, C. et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation120, 1203\u20131212. https:\/\/doi.org\/10.1161\/circulationaha.108.843334 (2009).","journal-title":"Circulation"},{"key":"74191_CR31","doi-asserted-by":"publisher","unstructured":"McDonagh, T. A. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J.42, 3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368 (2021).","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"74191_CR32","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","volume":"84","author":"H Kitaoka","year":"2020","unstructured":"Kitaoka, H. et al. JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. Circ. J.84, 1610\u20131671. https:\/\/doi.org\/10.1253\/circj.CJ-20-0110 (2020).","journal-title":"Circ. J."},{"key":"74191_CR33","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","volume":"24","author":"RK Patel","year":"2022","unstructured":"Patel, R. K. et al. Sex differences among patients with transthyretin amyloid cardiomyopathy\u2014from diagnosis to prognosis. Eur. J. Heart Fail.24, 2355\u20132363. https:\/\/doi.org\/10.1002\/ejhf.2646 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"74191_CR34","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1002\/ehf2.14364","volume":"10","author":"T Naito","year":"2023","unstructured":"Naito, T. et al. Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan. ESC Heart Fail.10, 1896\u20131906. https:\/\/doi.org\/10.1002\/ehf2.14364 (2023).","journal-title":"ESC Heart Fail."},{"key":"74191_CR35","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1002\/ehf2.14164","volume":"9","author":"H Yang","year":"2022","unstructured":"Yang, H. et al. An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction. ESC Heart Fail.9, 4280\u20134290. https:\/\/doi.org\/10.1002\/ehf2.14164 (2022).","journal-title":"ESC Heart Fail."},{"key":"74191_CR36","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/jnd-210656","volume":"8","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Hereditary transthyretin amyloidosis\u2014Clinical and genetic characteristics of a Multiracial South-East Asian Cohort in Singapore. J. Neuromuscul. Dis.8, 723\u2013733. https:\/\/doi.org\/10.3233\/jnd-210656 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"74191_CR37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/circulationaha.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy, Y. N. V., Carter, R. E., Obokata, M., Redfield, M. M. & Borlaug, B. A. A simple, evidence-based Approach to help Guide diagnosis of heart failure with preserved ejection fraction. Circulation138, 861\u2013870. https:\/\/doi.org\/10.1161\/circulationaha.118.034646 (2018).","journal-title":"Circulation"},{"key":"74191_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging16, 233\u2013270. https:\/\/doi.org\/10.1093\/ehjci\/jev014 (2015).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"74191_CR39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/ejechocard\/jeq175","volume":"12","author":"GG Blume","year":"2011","unstructured":"Blume, G. G. et al. Left atrial function: physiology, assessment, and clinical implications. Eur. J. Echocardiogr.12, 421\u2013430. https:\/\/doi.org\/10.1093\/ejechocard\/jeq175 (2011).","journal-title":"Eur. J. Echocardiogr."},{"key":"74191_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0002-8703(49)90562-1","volume":"37","author":"M Sokolow","year":"1949","unstructured":"Sokolow, M. & Lyon, T. P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am. Heart J.37, 161\u2013186. https:\/\/doi.org\/10.1016\/0002-8703(49)90562-1 (1949).","journal-title":"Am. Heart J."},{"key":"74191_CR41","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala, S. et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J. Nucl. Cardiol.26, 2065\u20132123. https:\/\/doi.org\/10.1007\/s12350-019-01760-6 (2019).","journal-title":"J. Nucl. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74191-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:02:45Z","timestamp":1727791365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74191-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74191"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74191-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3974254\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22863"}}